Evidence map›Paper›PMID 34788337›Full record

ArticlePLoS pathogens2021

ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection.

Dieter Mielke, Gama Bandawe, Jie Zheng, Jennifer Jones, Melissa-Rose Abrahams, Valerie Bekker, Christina Ochsenbauer, Nigel Garrett, Salim Abdool Karim, Penny L Moore and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cell-cell communication: new insights and clinical implications.Signal transduction and targeted therapy · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Dieter MielkeDepartment of Surgery, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0003-2182-0510
Gama BandaweInstitute of Infectious Diseases and Molecular Medicine and Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-8888-8048
Jie ZhengUniversity of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, United States of America.
Jennifer JonesUniversity of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, United States of America.
Melissa-Rose AbrahamsInstitute of Infectious Diseases and Molecular Medicine and Division of Medical Virology, University of Cape Town, Cape Town, South Africa.
Valerie BekkerNational Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0001-9951-1713
Christina OchsenbauerUniversity of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, United States of America.ORCID 0000-0003-1166-5879
Nigel GarrettCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.
Salim Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.ORCID 0000-0002-4986-2133
Penny L MooreNational Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0001-8719-4028
Lynn MorrisNational Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0003-3961-7828
David MontefioriDepartment of Surgery, Duke University, Durham, North Carolina, United States of America.
Colin AnthonyInstitute of Infectious Diseases and Molecular Medicine and Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0108-6251
Guido FerrariDepartment of Surgery, Duke University, Durham, North Carolina, United States of America.ORCID 0000-0001-7747-3349
Carolyn WilliamsonInstitute of Infectious Diseases and Molecular Medicine and Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-0125-1226
University of Cape Town · ZANational Health Laboratory Service · ZAUniversity of Alabama at Birmingham · USCentre for the AIDS Programme of Research in South Africa · ZADuke University · USNational Institute for Communicable Diseases

Funding

The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
NIAID NIH HHS U19 AI051794
6 · The paper itself

Abstract

Despite antibody-dependent cellular cytotoxicity (ADCC) responses being implicated in protection from HIV-1 infection, there is limited evidence that they control virus replication. The high mutability of HIV-1 enables the virus to rapidly adapt, and thus evidence of viral escape is a very sensitive approach to demonstrate the importance of this response. To enable us to deconvolute ADCC escape from neutralizing antibody (nAb) escape, we identified individuals soon after infection with detectable ADCC responses, but no nAb responses. We evaluated the kinetics of ADCC and nAb responses, and viral escape, in five recently HIV-1-infected individuals. In one individual we detected viruses that escaped from ADCC responses but were sensitive to nAbs. In the remaining four participants, we did not find evidence of viral evolution exclusively associated with ADCC-mediating non-neutralizing Abs (nnAbs). However, in all individuals escape from nAbs was rapid, occurred at very low titers, and in three of five cases we found evidence of viral escape before detectable nAb responses. These data show that ADCC-mediating nnAbs can drive immune escape in early infection, but that nAbs were far more effective. This suggests that if ADCC responses have a protective role, their impact is limited after systemic virus dissemination.

Indexed as

Antibody-Dependent Cell CytotoxicityImmune EvasionAntibodies, NeutralizingCD4-Positive T-LymphocytesHIV-1HIV AntibodiesHIV InfectionsHumansProspective StudiesVirus ReplicationAntibodies, NeutralizingHIV Antibodies

Identifiers

PMID34788337
PMCPMC8598021
OpenAlexW3211380382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.